TCON has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TCON has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. TRACON Pharmaceuticals's EBITDA for the three months ended in Dec. 2023 was $0.41 Mil. TRACON Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $3.05 Mil. Therefore, TRACON Pharmaceuticals's EBITDA margin for the quarter that ended in Dec. 2023 was 13.43%.
The historical data trend for TRACON Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TRACON Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EBITDA Margin % | Get a 7-Day Free Trial | - | - | -8,193.35 | - | 31.13 |
TRACON Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EBITDA Margin % | Get a 7-Day Free Trial | - | - | -8.57 | - | 13.43 |
For the Biotechnology subindustry, TRACON Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, TRACON Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where TRACON Pharmaceuticals's EBITDA Margin % falls into.
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
TRACON Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as
TRACON Pharmaceuticals's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TRACON Pharmaceuticals (NAS:TCON) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Thank you for viewing the detailed overview of TRACON Pharmaceuticals's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Opaleye Management Inc. | 10 percent owner | ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108 |
Charles Theuer | director, officer: President and CEO | C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122 |
Bonne J. Adams | officer: Chief Operating Officer | C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122 |
Scott B. Brown | officer: Chief Accounting Officer (PAO) | C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122 |
William R Larue | director | C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, SUITE 700, SAN DIEGO CA 92122 |
Carol C. Lam | director | C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, STE 800, SAN DIEGO CA 92122 |
Saundra L Pelletier | director | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130 |
Lisa Johnson-pratt | director | C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122 |
Ikarian Healthcare Master Fund, L.p. | 10 percent owner, other: Member of 10% Group | 100 CRESCENT COURT, SUITE 1620, DALLAS TX 75201 |
Mark C Wiggins | officer: Chief Business Officer | 12671 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA 92130 |
Neil Shahrestani | 10 percent owner, other: Member of 10% Group | 12806 WINDING CREEK DRIVE, FRISCO TX 75035 |
Ikarian Healthcare Fund Gp, L.p. | 10 percent owner, other: Member of 10% Group | 100 CRESCENT COURT, SUITE1620, DALLAS TX 75201 |
Chart Westcott Living Trust | 10 percent owner, other: Member of 10% Group | 100 CRESCENT COURT, SUITE1620, DALLAS TX 75201 |
Ikarian Capital, Llc | 10 percent owner, other: Member of 10% Group | 100 CRESCENT COURT, SUITE 1620, DALLAS TX 75201 |
Puissance Cross-border Opportunities V Llc | 10 percent owner | 950 THIRD AVENUE, 25TH FL, NEW YORK NY 10022 |
From GuruFocus
By PurpleRose PurpleRose • 07-27-2022
By GuruFocus Research GuruFocus Editor • 10-11-2022
By sperokesalga sperokesalga • 06-16-2023
By Ds*** Ds*** • 08-29-2022
By sperokesalga sperokesalga • 02-28-2023
By Business Wire Business Wire • 08-30-2022
By sperokesalga sperokesalga • 05-03-2023
By PurpleRose PurpleRose • 07-26-2022
By PurpleRose PurpleRose • 07-12-2022
By PurpleRose PurpleRose • 07-15-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.